Patients with advanced or recurrent solid tumors who are candidates for systemic therapy and are not eligible to undergo comprehensive genomic profiling (CGP) testing under the national insurance system before completion (or anticipated completion) of standard treatment.
Conditions
Interventions
Japan-approved comprehensive genomic profiling (CGP) tests
Sponsors
Okayama University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with advanced or recurrent solid tumors who are candidates for systemic therapy. 2. No prior comprehensive genomic profiling (CGP) testing reimbursed under the national health insurance system. 3. The treating physician determines that the patient is not currently eligible for insurance-covered CGP testing under the prevailing reimbursement criteria at the time of study enrollment. 4. Availability of specimens suitable for genomic analysis, including archived tumor tissue and/or newly collected peripheral blood samples. 5. Willingness to have clinical and genomic data registered in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database and utilized for research purposes. 6. Provision of written informed consent by the patient prior to participation in the study.
Exclusion criteria
Exclusion criteria: Patients who have previously enrolled in this study and undergone CGP testing under the framework of Advanced Medical Care A.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients who received molecularly targeted therapy for actionable genomic alterations identified by CGP testing performed in this study. | — |
Countries
Japan
Contacts
Public ContactKiichiro Ninomiya
Okayama University Hospital Center for Comprehensive Genomic Medicine
Outcome results
None listed